A 12-week probiotic intervention with Bifidobacterium breve BBr60 significantly increased GLP-1, PYY, and other metabolic hormones while reducing insulin resistance in obese individuals through gut microbiota and short-chain fatty acid modulation.
GLP-1 significantly elevated (p<0.05)Endogenous GLP-1 levels increased after 12 weeks of probiotic supplementation via butyrate-mediated gut microbiota remodeling in obese individuals
What the researchers found
After 12 weeks, the BBr60 group showed significantly increased fecal butyrate levels (p < 0.001), which correlated with increased GLP-1 and IL-27 levels. Multiple metabolic peptide hormones were significantly elevated in the probiotic group: leptin, adiponectin, C-peptide, pancreatic polypeptide, peptide YY, GIP, and GLP-1 (all p < 0.05). HOMA-IR (insulin resistance) was significantly reduced (p < 0.05).
The anti-inflammatory cytokine IL-27 was upregulated (p < 0.01) while the pro-inflammatory IL-1β was decreased (p < 0.05). In the placebo group, only C-peptide, pancreatic polypeptide, and GIP increased, with no changes in leptin, adiponectin, PYY, GLP-1, or HOMA-IR. Butyrate levels positively correlated with GLP-1 and IL-27, and negatively with IL-1β.
Why it matters
GLP-1 receptor agonist drugs like semaglutide and tirzepatide are revolutionary for obesity, but they require injections or expensive prescriptions. This study suggests that specific probiotics can naturally boost the body's own production of GLP-1 and other metabolic peptides by improving gut health. This could offer a complementary, accessible approach to improving metabolic function in obesity.
How the study worked
A randomized, double-blind, placebo-controlled trial enrolled 75 individuals with obesity (BMI ≥ 28), with 65 completing the study (33 BBr60, 32 placebo). The intervention group received 10 billion CFU of Bifidobacterium breve BBr60 daily for 12 weeks. All participants received standardized nutritional counseling (~1800 kcal/day, 25g fiber) with weekly phone check-ins. Gut microbiota was analyzed by 16S sequencing, fecal short-chain fatty acids by GC-MS, and serum hormones and cytokines by ELISA.
What this study cannot tell us
The sample size was modest (65 completers). The study was 12 weeks — long-term effects and sustainability of metabolic improvements are unknown. While many peptide hormones increased, the abstract doesn't report actual weight loss or body fat changes, making it hard to assess clinical significance. The ~1800 kcal/day dietary counseling may have contributed to results in both groups. The specific mechanisms connecting butyrate to each hormone require further investigation.
How to read the evidence
This is a randomized, double-blind, placebo-controlled trial — the gold standard for intervention studies. However, the sample size is relatively small (65 completers), and key clinical outcomes like weight loss are not clearly reported in the abstract.
When this study was published
Published in 2025, this is a very recent study reflecting the cutting edge of research on the gut microbiota-peptide hormone axis in obesity.
The bigger picture
The connection between gut bacteria, short-chain fatty acids, and metabolic hormones is a rapidly growing field. This study provides human clinical trial evidence linking a specific probiotic to increased endogenous GLP-1 and other peptide hormones through a defined mechanistic pathway. As GLP-1-based therapies dominate the obesity treatment landscape, understanding how to naturally boost GLP-1 through gut health could complement pharmacological approaches.
Questions still open
- Does the probiotic-induced increase in GLP-1 translate to meaningful weight loss or improved glycemic control over longer periods?
- Could Bifidobacterium breve BBr60 be used alongside GLP-1 receptor agonist medications to enhance their effects?
- What specific gut microbiota changes drive the butyrate increase, and are these changes sustained after stopping the probiotic?
Common questions
Can a probiotic really increase GLP-1 levels like the weight loss drugs do?
What is butyrate and why does it matter for metabolic hormones?
Read the original research
Bifidobacterium Breve BBr60 Improves Obesity Via the Gut Microbiota-Short-Chain Fatty Acid-IL-27/GLP-1 Axis: Evidence from a Randomized, Double-Blind, Placebo-Controlled Trial.
Probiotics and antimicrobial proteins
Citation
Gao, Dejiao; Dong, Yao; Jia, Zhumin; Bian, Chenying; Zhu, Jianguo; Wu, Ying; Fang, Shuguang; Gu, Shaobin. (2025). Bifidobacterium Breve BBr60 Improves Obesity Via the Gut Microbiota-Short-Chain Fatty Acid-IL-27/GLP-1 Axis: Evidence from a Randomized, Double-Blind, Placebo-Controlled Trial.. Probiotics and antimicrobial proteins. https://doi.org/10.1007/s12602-025-10885-9